Verified October 27, 2026

Which peptides can
legally be compounded?

Short answer, as of October 27, 2026: none of the six under review. On 30 July 2026 the FDA's Pharmacy Compounding Advisory Committee voted to recommend six peptides for the 503A Bulks List. A recommendation is not an approval, and the FDA had not begun formal rulemaking. Anyone telling you otherwise is ahead of the record.

The July 2026 vote

What the committee actually decided

PeptideFDA status Committee vote
BPC-157 Synthetic pentadecapeptide (gastric-derived) Not FDA-approved Recommended 30 Jul 2026
Epitalon Pineal tetrapeptide (Ala-Glu-Asp-Gly) Not FDA-approved Recommended 30 Jul 2026
KPV Anti-inflammatory tripeptide Not FDA-approved Recommended 30 Jul 2026
MOTS-c Mitochondrial-derived peptide Not FDA-approved Recommended 30 Jul 2026
Semax Nootropic peptide (ACTH(4-10) analog) Not FDA-approved Recommended 30 Jul 2026
TB-500 Synthetic Tβ4 fragment Not FDA-approved Recommended 30 Jul 2026

Questions

What people are actually asking

Can BPC-157 be legally compounded right now?

No. It was recommended by FDA's Pharmacy Compounding Advisory Committee on 30 July 2026, but a recommendation is not an approval. On 30 October 2026 HHS published a notice of availability for a DRAFT interim enforcement discretion policy on 503A compounding using certain peptide bulk drug substances (Federal Register, Docket HHS-OASH-2026-0496), open for comment for two weeks. A draft interim enforcement policy is not FDA approval.

Which peptides did the FDA advisory committee recommend in July 2026?

Six: BPC-157, Epitalon, KPV, MOTS-c, Semax, TB-500. Emideltide was reviewed and not recommended.

How long does the rulemaking take?

Formal FDA rulemaking after a committee recommendation typically runs 8 to 24 months. Nothing changes legally until it completes.

See all 150 peptides, mapped to the body.

Every one with its regulatory status read off FDA label data, and its sources listed.

Open the library

Educational reference only. This page reports the regulatory record. It is not legal advice, not medical advice, and carries no dosing information. OPTML does not offer or supply the compounds under review.

Treatment decisions are made by a licensed physician after an individual evaluation. Compounded preparations are not FDA-approved or evaluated by the FDA for safety, effectiveness, or quality. Individual results vary.